ESC 365 - Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks - rebuttal and discussion.

EHRA Premium Access

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks - rebuttal and discussion.

Session: Controversies in ventricular tachycardia (VT) ablation

Topic: Catheter Ablation of Arrhythmias

Event: EHRA 2022

Congress Presentation

Add to my library

5 more presentations in this session

What will improve the results of VT ablation? Better mapping.

Speaker: Doctor P. Maury (Toulouse, FR)

What will improve the results of VT ablation? Better technology.

Speaker: Professor J. Kautzner (Prague, CZ)

What will improve the results of VT ablation? - rebuttal and discussion.

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: drugs?

Speaker: Professor A. Goette (Paderborn, DE)

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: ablation?

Speaker: Doctor M. Saba (New Malden, GB)

Access the full session

Controversies in ventricular tachycardia (VT) ablation

Speakers: Doctor P. Maury, Professor J. Kautzner, Professor A. Goette, Doctor M. Saba

About the event

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources